Brief: LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq
12/09/2025 13:10
Sept 12 (Reuters) - LakeShore Biopharma Co Ltd H6Z0.F: LAKESHORE BIOPHARMA ANNOUNCES RECEIPT OF DELISTING DETERMINATION LETTER FROM NASDAQ Source text: ID:nPnJn20ga Further company coverage: H6Z0.F ((Reuters.Briefs@thomsonreuters.com;))
Recent news on LakeShore Biopharma Co
See all newsBrief: LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq
Brief: LakeShore Biopharma Appoints Advisors to Special Committee Reviewing Takeover Bid
Brief: Lakeshore Biopharma Announces Receipt Of A Preliminary Non-Binding Proposal To Acquire The Company
Brief: Lakeshore Biopharma Expects 2026 Revenue To Be Between RMB550 Million And RMB650 Million
Brief: Lakeshore Biopharma Announces Us$15 Million Private Placement Financing